Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 6,500 shares, a drop of 15.6% from the January 31st total of 7,700 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 12,400 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Xenetic Biosciences Stock Down 1.5 %

NASDAQ:XBIO opened at $3.83 on Thursday. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20. The stock’s 50 day moving average price is $4.11 and its 200 day moving average price is $4.03. The company has a market capitalization of $5.91 million, a PE ratio of -1.44 and a beta of 2.17.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC boosted its stake in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,550 shares of the company’s stock after acquiring an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 as of its most recent filing with the Securities and Exchange Commission. 15.12% of the stock is owned by hedge funds and other institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.